Top

BMC Pediatrics

Published in:

Open Access 01-12-2021 | Patent Ductus Arteriosus | Research

Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial

Authors: Solomiia Potsiurko, Dmytro Dobryanskyy, Lesya Sekretar

Published in: BMC Pediatrics | Issue 1/2021

Abstract

Background

Patent ductus arteriosus (PDA) is a common complication in very preterm infants. It is known that there is an association between PDA and development of bronchopulmonary dysplasia (BPD) or death before the postmenstrual age (PMA) of 36 weeks, but this association remains one of the most controversial aspects of the problem. The study aimed to evaluate the relationship between PDA, serum NT-proBNP levels at 2–3 and 8–9 days of life, and BPD/death in very preterm infants.

Methods

Data of 52 preterm infants with a gestational age < 32 weeks, chronological age < 72 h, and PDA diameter > 1.5 mm, enrolled in a randomized controlled trial, were used for the retrospective analysis. All patients underwent daily echocardiographic and two serum NT-proBNP measurements within the first 10 days after birth. Two groups of infants were formed retrospectively at PMA of 36 weeks depending on the outcome, BPD (n = 18)/death (n = 7) or survival without BPD (n = 27). Receiver operator characteristic (ROC) curve was used to evaluate the predictive performance of serum NT-proBNP levels for BPD/death occurrence.

Results

The percentage of infants who received pharmacological treatment for PDA did not differ between the groups. Based on the area under the ROC curve, serum NT-proBNP levels on the 2–3 day of life (AUC = 0.71; 95% confidence interval (CI): 0.56–0.9; p = 0.014)) and on the 8–9 day of life (AUC = 0.76; 95% CI: 0.6–0.9; p = 0.002) could reliably predict BPD/death in very preterm infants who had PDA diameter > 1.5 mm in the first 72 h of life. Hemodynamically significant PDA (hsPDA) was significantly more often detected in newborns with BPD/death, however, treatment of infants with hsPDA did not reduce the incidence of BPD/death.

Conclusions

In very preterm infants with PDA > 1.5 mm at the age of 24–48 h, serum NT-proBNP concentration could reliably predict the development of BPD or death, regardless of the persistence of PDA, with the highest diagnostic value at 8–9 days.

Trial registration

This study is registered in ClinicalTrials.gov - NCT03860428 on March 4, 2019.

Sung SI, Chang YS, Chun JY, Yoon SA, Yoo HS, Ahn SY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr. 2016;177:66–71.e1. https://doi.org/10.1016/j.jpeds.2016.06.046.CrossRefPubMed

Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr. 2015;166(6):1488–92. https://doi.org/10.1016/j.jpeds.2015.03.012.CrossRefPubMed

Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Høst B, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F505–10. https://doi.org/10.1136/archdischild-2013-303816.CrossRefPubMed

Willis KA, Weems MF. Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia. Congenit Heart Dis. 2019;14(1):27–32. https://doi.org/10.1111/chd.12691.CrossRefPubMed

Clyman RI, Hills NK, Liebowitz M, Johng S. Relationship between duration of infant exposure to a moderate-to-large patent Ductus Arteriosus shunt and the risk of developing Bronchopulmonary dysplasia or death before 36 weeks. Am J Perinatol. 2020;37(2):216–23. https://doi.org/10.1055/s-0039-1697672.CrossRefPubMed

Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2019;6:CD004213. https://doi.org/10.1002/14651858.CD004213.pub4.CrossRefPubMed

Farooqui MA, Elsayed YN, Jeyaraman MM, Dingwall O, Tagin M, Zarychanski R. Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: a systematic review and meta-analysis. J Neonatal Perinatal Med. 2019;12(1):1–7. https://doi.org/10.3233/NPM-17130.CrossRefPubMed

Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41–8.e6. https://doi.org/10.1016/j.jpeds.2018.09.012.CrossRefPubMed

Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014;100(3):145–57. https://doi.org/10.1002/bdra.23235.CrossRefPubMed

10.

Rivera L, Siddaiah R, Oji-Mmuo C, Silveyra GR, Silveyra P. Biomarkers for Bronchopulmonary dysplasia in the preterm infant. Front Pediatr. 2016;4:33. https://doi.org/10.3389/fped.2016.00033.CrossRefPubMedPubMedCentral

11.

Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics. 2015;135(2):e510–25. https://doi.org/10.1542/peds.2014-1995.CrossRefPubMed

12.

Rodríguez-Blanco S, Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Palau-Benavides M. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: a prospective observational study. Pediatr Pulmonol. 2018;53(8):1073–81. https://doi.org/10.1002/ppul.24053.CrossRefPubMed

13.

Xiong T, Kulkarni M, Gokulakrishnan G, Shivanna B, Pammi M. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review. J Perinatol. 2020;40(4):607–15. https://doi.org/10.1038/s41372-019-0588-2.CrossRefPubMed

14.

Hundscheid T, Onland W, van Overmeire B, Dijk P, van Kaam AHLC, Dijkman KP, et al. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial). BMC Pediatr. 2018;18(1):262. https://doi.org/10.1186/s12887-018-1215-7.CrossRefPubMedPubMedCentral

15.

Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–9. https://doi.org/10.1164/ajrccm.163.7.2011060.CrossRefPubMed

16.

Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23(6):451–6. https://doi.org/10.1038/sj.jp.7210963.CrossRefPubMed

17.

Arlettaz R. Echocardiographic evaluation of patent Ductus Arteriosus in preterm infants. Front Pediatr. 2017;5:147. https://doi.org/10.3389/fped.2017.00147.CrossRefPubMedPubMedCentral

18.

Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 2012;101(3):247–51. https://doi.org/10.1111/j.1651-2227.2011.02468.x.CrossRefPubMed

19.

Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risks cores. J Pediatr. 2001;138(1):92–100. https://doi.org/10.1067/mpd.2001.109608.CrossRefPubMed

20.

Clyman R. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol. 2013;37(2):102–7. https://doi.org/10.1053/j.semperi.2013.01.006.CrossRefPubMedPubMedCentral

21.

Härkin P, Marttila R, Pokka T, Saarela T, Hallman M. Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study. J Matern Fetal Neonatal Med. 2018;31(19):2576–83. https://doi.org/10.1080/14767058.2017.1347921.CrossRefPubMed

22.

Smith A, El-Khuffash A. Defining “Haemodynamic significance” of the patent Ductus Arteriosus: do we have all the answers? Neonatology. 2020;117(2):1–8. https://doi.org/10.1159/000506988.CrossRef

23.

El-Khuffash A, James AT, Corcoran JD, Dicker P, Franklin O, Elsayed YN, et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. J Pediatr. 2015;167(6):1354–1361.e2. https://doi.org/10.1016/j.jpeds.2015.09.028.CrossRefPubMed

24.

McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F424–7. https://doi.org/10.1136/adc.2007.118117.CrossRefPubMedPubMedCentral

25.

Mirza H, Garcia J, McKinley G, Hubbard L, Sensing W, Schneider J, et al. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol. 2019;39(12):1648–55. https://doi.org/10.1038/s41372-019-0496-5.CrossRefPubMed

26.

Wai KC, Kohn MA, Ballard RA, Truog WE, Black DM, Asselin JM, et al. Early cumulative supplemental oxygen predicts bronchopulmonary dysplasia in high risk extremely low gestational age newborns. J Pediatr. 2016;177:97–102.e2. https://doi.org/10.1016/j.jpeds.2016.06.079.CrossRefPubMedPubMedCentral

27.

Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Rodríguez-Blanco S. Early assessment of lung aeration using an ultrasound score as a biomarker of developing bronchopulmonary dysplasia: a prospective observational study. J Perinatol. 2021;41(1):62–8. https://doi.org/10.1038/s41372-020-0724-z.CrossRefPubMed

28.

Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, et al. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr. 2018;177(4):521–32. https://doi.org/10.1007/s00431-018-3089-y.CrossRefPubMed

29.

Zhou L, Xiang X, Wang L, Chen X, Zhu J, Xia H. N-terminal pro-B-type natriuretic peptide as a biomarker of Bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front Pediatr. 2019;7:166. https://doi.org/10.3389/fped.2019.00166.CrossRefPubMedPubMedCentral

Title: Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial
Authors: Solomiia Potsiurko
Dmytro Dobryanskyy
Lesya Sekretar
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Patent Ductus Arteriosus
Patent Ductus Arteriosus
Patent Ductus Arteriosus
Patent Ductus Arteriosus
Published in: BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI: https://doi.org/10.1186/s12887-021-02750-9

At a glance: The STEP trials

Springer Medicine

Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Prevalence of bone fractures among children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis

Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia

Childhood obesity prevention policies in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams

Reference intervals for hemoglobin and mean corpuscular volume in an ethnically diverse community sample of Canadian children 2 to 36 months

Fatal accidental lipid overdose with intravenous composite lipid emulsion in a premature newborn: a case report

Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change